Thank you for your interest in the article entitled "New therapeutic agents in diabetic nephropathy" \[[@b1-kjim-2017-154]\] and your comments on erroneous information therein. We agree that there are several errors in the article; therefore, we have made the following revisions according to your comments.

The ongoing 'Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria' (PRIORITY) trial is investigating the efficacy of the mineralocorticoid receptor antagonist (MRA) spironolactone, in terms of delaying the progression of early diabetic nephropathy (DN) \[[@b2-kjim-2017-154]\]. However, concerns regarding the development of hyperkalemia in those with decreased renal function need to be addressed. The nonsteroidal MRA finerenone (BAY 94-8862) was well-tolerated in a Japanese population with DN and did not exert adverse effects on serum potassium levels or renal function \[[@b3-kjim-2017-154],[@b4-kjim-2017-154]\]. A study of the safety of the selective aldosterone receptor antagonist MT-3995 regarding the development of hyperkalemia in subjects with DN is required \[[@b5-kjim-2017-154]\].

We appreciate your interest in, and comments on, our article and we hope that our revisions have addressed your concerns.
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